Virodacla 60 mg (Tablet)
Unit Price: ৳ 400.00 (3 x 4: ৳ 4,800.00)
Strip Price: ৳ 1,600.00
Medicine Details
Category | Details |
---|---|
Generic | Daclatasvir |
Company | Incepta pharmaceuticals ltd |
Indications
- Treatment of chronic hepatitis C virus (HCV) infection in adults
Pharmacology
- Direct acting antiviral agent (DAA) against the Hepatitis C Virus (HCV)
- Inhibitor of NS5A, a nonstructural protein encoded by HCV
- Binds to the N-terminus of NS5A and inhibits viral RNA replication and virion assembly
Dosage & Administration
- Recommended dosage of 60mg once daily, to be taken orally with or without meals
- Administered in combination with other medicinal products
- Dose modification and interruption guidelines
Interaction
- Substrate of CYP3A
- Inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP)
Contraindications
- Contraindicated in combination with drugs that strongly induce CYP3A
- Includes anticonvulsants, antimycobacterial agents, and herbal products like st.Jhon’s wort (Hypericum perforatum)
Side Effects
- Serious symptomatic bradycardia when coadministered with Sofosbuvir and Amiodarone
- Symptoms may include fainting, dizziness, weakness, chest pain, confusion
Pregnancy & Lactation
- No data available for pregnant women or breastfeeding
- Effects on the breastfed infant or milk production is unknown
Precautions & Warnings
- Risk of adverse reactions or loss of virologic response due to drug interactions
- Potential for known or potentially significant drug interactions
- Serious symptomatic bradycardia when coadministered with Sofosbuvir and Amiodarone
Use in Special Populations
- No dose adjustment required for elderly patients and those with renal impairment
- No dose adjustment for patients with mild to severe hepatic impairment
- Safety and efficacy in children and adolescents below 18 years not established
Overdose Effects
- No known antidote for overdose
- Treatment should consist of general supportive measures
- Dialysis unlikely to significantly reduce plasma concentrations
Therapeutic Class
- Hepatic viral infections (Hepatitis C)
Storage Conditions
- Store at room temperature below 30°C
- Protect from light
- Keep out of the reach of children